Table 1 Flow cytometry panels used in the study.
Panel | Commercial/ prototype | Conjugates | Format | Cytometer | |
|---|---|---|---|---|---|
Phenotyping | Infection related panel (surface) | Myeloid activation test + CD43 | CD169-PE, HLA-DR-APC, CD64-PB, and CD43-AF750 | Liquid | NAVIOS |
Granulocyte panel (surface) | DURAClone IM Granulocytes | CD294-FITC, CD16-ECD, CD33-PC5.5, CD11b-PC7, CD274-APC, CD3-CD19-CD56-CD14 APC-AF700, CD62L-APC-AF750, CD15-PB, and CD45-KrO | Dried | NAVIOS | |
T cell subset panel (surface) | DURAClone IM T cell subset | CD45RA-FITC, CD197-PE, CD28-ECD, CD279-PC5.5, CD27-PC7, CD4-APC, CD8-AF700, CD3-APC-AF750, CD57-PB, and CD45-KrO | Dried | NAVIOS | |
B cell subset panel (surface) | DURAClone IM B cells | IgD-FITC, CD21-PE, CD19-ECD, CD27-PC7, CD24-APC, CD38-APC-AF750, IgM-PB, and CD45-KrO | Dried | NAVIOS | |
Dendritic cell panel (surface) | DURAClone IM Dendritic cells | CD16-FITC, CD3-CD14-CD19-CD20- CD56-PE, CD1c-PC5.5, CD11c-PC7, Clec 9A-APC, CD123-APC-AF700, HLA-DR-PB, and CD45-KrO; | Dried | NAVIOS | |
Treg panel (intracellular) | DURAClone IM Treg | CD45RA-FITC, CD25-PE, CD39-PC5.5, CD4-PC7, FoxP3-A647, CD3-APC-AF750, Helios-PB, and CD45-KrO | Dried | NAVIOS | |
Phenotyping + functional analysis | Leukocyte activation panel (surface) | Prototype | CD54-FITC, CD11b-PE, CD16-ECD, CD56-PC5.5, CD69-PC7, CD62L-APC, tmTNF-AF700, CD3-CD66b-APC-AF750, CD14-PB, and CD45-KrO | Liquid | CytoFLEX |
Granulocyte activation panel (surface) | Prototype | DHR123-FITC**, MPO-PE, CD62L-ECD, CD11b-PC7, CD294-AF647, CD16-APC-AF700, CD66b-APC-AF750, DAPI-PB, and CD45-KrO | Liquid | CytoFLEX | |
Cytokine activation panel (intracellular) | Prototype | IL8-A488*, IL6-PE*, CD14-ECD, IL4-PC7, CD3-APC, TNFa-A700, IFNγ-PB, and CD8-CD45-KrO | Liquid | NAVIOS | |
Infection related panel (surface) | Myeloid activation test + CD43 | CD169-PE, HLA-DR-APC, CD64-PB, and CD43-AF750 | Liquid | NAVIOS |
